| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Eur J Cardiothorac Surg 2007;31:141. doi:10.1016/j.ejcts.2006.10.027
Copyright © 2007, European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved
Letters to the Editor |
Georges Pompidou European Hospital, 20 rue Leblanc, 75015 Paris, France
Received 8 October 2006; accepted 25 October 2006.
* Corresponding author. Tel.: +33 1 56 09 34 50. (Email: marc.riquet{at}hop.egp.ap-hop-paris.fr).
Key Words: Octogenarians • Pneumonectomy • TNM
The experience of Matsuoka et al. [1] with resections for lung cancer in octogenarians (n = 40) was characterised by 20% non-lethal complications (n = 8), 40% lobectomies (n = 16), 60% segmentectomies and wedge (n = 12 each), no pneumonectomy. There were 22 adenocarcinomas (55%), 11 squamous (27.5%), 4 large-cell (10%), 2 adenosquamous (5%), 1 neuroendocrine (2.5%) cell carcinomas and essentially pStage I disease (n = 35, 87.5%; pStage II n = 3, 7.5% and III n = 2, 5%); actuarial 5-year survival was 56.9%. These good results were clearly attributable to their case selection, as stressed by Shanmugam et al. [2] who considered it fortunate that no patient required a pneumonectomy and wondered whether it was worth operating on the octogenarians with N2 malignant lymphadenopathy.
Between 1984 and 2003, the authors operated on 66 octogenarians (curative resection with mediastinal lymphadenectomy): pneumonectomy n = 23 (34.8%), lobectomy n = 42 (65.6%) and segmentectomy n = 1. Postoperative complications (1 month or same hospital stay) was 31.8% (n = 21), including 7.6% deaths (n = 5): pneumonectomy 8.7% (2/23) and lobectomy 7.1% (3/42). There were 22 adenocarcinomas (30.3%), 34 squamous (51.5%), 6 large-cell (9.1%), 1 adenosquamous (1.5%), 5 neuroendocrine (7.6%) cell carcinomas. pStage I was 54.5% (n = 36), pStage II 19.7% (n = 13) and Stage III 25.8% (n = 17, of which N2 = 13 or 20%). Complications and postoperative deaths by stage were, respectively, Stage I 36.1% (13/36) including two deaths (5.5%), Stage II 30.8% (4/13) one death (7.7%), Stage III 23.5% (4/17) two deaths (11.8%) (NS). The whole series actuarial 5-year survival rate was 29.1% (median 26 months): Stage I 40.6%(median 42); Stage II 36.9% (median 26), Stage III 0% (median 11 months) (p = 0.0040).
This short series permits to answer Shanmugam et al.'s [2] question by confirming that there is no surgery benefit for N2 octogenarians. It may also suggest explanations for Matsuoka et al.'s [1] reply wondering why the ratio of pneumonectomy was so high in Europe, by illustrating a not so strict patients selection while taking care to preserve the best risk-benefits balance, and by also illustrating a well-known histologic pattern difference [3], which is more squamous cell carcinomas than adenocarcinomas in Europe, (as in authors’ series, respectively 51.5% and 30.3% versus 27.5% and 55%, p = 0.026), and which correlates with more proximal than peripheral lung cancers.
References
This article has been cited by other articles:
|
|
 |
|
  H. Matsuoka Reply to Riquet et al. Eur. J. Cardiothorac. Surg., January 1, 2007; 31(1): 141 - 141. [Full Text] [PDF]
|
|
|
|
|
|
G. Shanmugam Reply to Riquet et al. Eur. J. Cardiothorac. Surg., January 1, 2007; 31(1): 142 - 142. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
